AFFIMED NV (AFMD) Fundamental Analysis & Valuation

NASDAQ:AFMD • NL0015001ZQ0

Current stock price

0.1815 USD
-0.1 (-34.95%)
At close:
0.1731 USD
-0.01 (-4.63%)
After Hours:

This AFMD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. AFMD Profitability Analysis

1.1 Basic Checks

  • AFMD had negative earnings in the past year.
  • AFMD had a negative operating cash flow in the past year.
  • AFMD had negative earnings in each of the past 5 years.
  • In the past 5 years AFMD always reported negative operating cash flow.
AFMD Yearly Net Income VS EBIT VS OCF VS FCFAFMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M

1.2 Ratios

  • AFMD has a Return On Assets of -175.10%. This is amonst the worse of the industry: AFMD underperforms 87.32% of its industry peers.
  • AFMD's Return On Equity of -406.92% is on the low side compared to the rest of the industry. AFMD is outperformed by 75.89% of its industry peers.
Industry RankSector Rank
ROA -175.1%
ROE -406.92%
ROIC N/A
ROA(3y)-59.16%
ROA(5y)-45.97%
ROE(3y)-93.94%
ROE(5y)-84.6%
ROIC(3y)N/A
ROIC(5y)N/A
AFMD Yearly ROA, ROE, ROICAFMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

  • With an excellent Gross Margin value of 789.74%, AFMD belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • In the last couple of years the Gross Margin of AFMD has declined.
  • AFMD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 789.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.76%
GM growth 5Y-2.54%
AFMD Yearly Profit, Operating, Gross MarginsAFMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. AFMD Health Analysis

2.1 Basic Checks

  • AFMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, AFMD has about the same amount of shares outstanding.
  • The debt/assets ratio for AFMD is higher compared to a year ago.
AFMD Yearly Shares OutstandingAFMD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M
AFMD Yearly Total Debt VS Total AssetsAFMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

  • Based on the Altman-Z score of -4.35, we must say that AFMD is in the distress zone and has some risk of bankruptcy.
  • AFMD's Altman-Z score of -4.35 is in line compared to the rest of the industry. AFMD outperforms 44.64% of its industry peers.
  • A Debt/Equity ratio of 0.35 indicates that AFMD is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.35, AFMD is doing worse than 73.04% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF N/A
Altman-Z -4.35
ROIC/WACCN/A
WACC6.81%
AFMD Yearly LT Debt VS Equity VS FCFAFMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M -100M 150M

2.3 Liquidity

  • AFMD has a Current Ratio of 1.93. This is a normal value and indicates that AFMD is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of AFMD (1.93) is worse than 76.79% of its industry peers.
  • AFMD has a Quick Ratio of 1.93. This is a normal value and indicates that AFMD is financially healthy and should not expect problems in meeting its short term obligations.
  • AFMD has a worse Quick ratio (1.93) than 75.36% of its industry peers.
Industry RankSector Rank
Current Ratio 1.93
Quick Ratio 1.93
AFMD Yearly Current Assets VS Current LiabilitesAFMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. AFMD Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 42.15% over the past year.
  • Looking at the last year, AFMD shows a very negative growth in Revenue. The Revenue has decreased by -95.39% in the last year.
  • Measured over the past years, AFMD shows a very negative growth in Revenue. The Revenue has been decreasing by -19.00% on average per year.
EPS 1Y (TTM)42.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.25%
Revenue 1Y (TTM)-95.39%
Revenue growth 3Y-33.67%
Revenue growth 5Y-19%
Sales Q2Q%-92.1%

3.2 Future

  • The Earnings Per Share is expected to grow by 11.18% on average over the next years. This is quite good.
  • AFMD is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 35.57% yearly.
EPS Next Y40.97%
EPS Next 2Y28.77%
EPS Next 3Y19.02%
EPS Next 5Y11.18%
Revenue Next Year-81.84%
Revenue Next 2Y-23.09%
Revenue Next 3Y14.98%
Revenue Next 5Y35.57%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AFMD Yearly Revenue VS EstimatesAFMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
AFMD Yearly EPS VS EstimatesAFMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4 -6 -8 -10

More info and screens

Find the best growth stocksShow best growing peers

0

4. AFMD Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for AFMD. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AFMD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AFMD Price Earnings VS Forward Price EarningsAFMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AFMD Per share dataAFMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4

4.3 Compensation for Growth

  • AFMD's earnings are expected to grow with 19.02% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.77%
EPS Next 3Y19.02%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AFMD Dividend Analysis

5.1 Amount

  • No dividends for AFMD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

AFMD Fundamentals: All Metrics, Ratios and Statistics

AFFIMED NV

NASDAQ:AFMD (5/19/2025, 8:00:00 PM)

After market: 0.1731 -0.01 (-4.63%)

0.1815

-0.1 (-34.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-02
Earnings (Next)06-09
Inst Owners22.64%
Inst Owner Change-98.95%
Ins Owners6.01%
Ins Owner ChangeN/A
Market Cap2.76M
Revenue(TTM)877.00K
Net Income(TTM)-69.97M
Analysts84
Price Target12.24 (6643.8%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.56%
Min EPS beat(2)-10.88%
Max EPS beat(2)1.75%
EPS beat(4)3
Avg EPS beat(4)4.52%
Min EPS beat(4)-10.88%
Max EPS beat(4)14.22%
EPS beat(8)4
Avg EPS beat(8)1.65%
EPS beat(12)7
Avg EPS beat(12)6.57%
EPS beat(16)8
Avg EPS beat(16)-11.38%
Revenue beat(2)0
Avg Revenue beat(2)-90.72%
Min Revenue beat(2)-92.4%
Max Revenue beat(2)-89.04%
Revenue beat(4)0
Avg Revenue beat(4)-85.87%
Min Revenue beat(4)-92.4%
Max Revenue beat(4)-74.24%
Revenue beat(8)2
Avg Revenue beat(8)-47.19%
Revenue beat(12)4
Avg Revenue beat(12)-23.39%
Revenue beat(16)7
Avg Revenue beat(16)-15.7%
PT rev (1m)0%
PT rev (3m)-11.76%
EPS NQ rev (1m)-5.91%
EPS NQ rev (3m)-5.91%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-83.93%
Revenue NQ rev (3m)-83.93%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.78
P/FCF N/A
P/OCF N/A
P/B 0.14
P/tB 0.14
EV/EBITDA N/A
EPS(TTM)-5.18
EYN/A
EPS(NY)-2.73
Fwd EYN/A
FCF(TTM)-5.77
FCFYN/A
OCF(TTM)-5.73
OCFYN/A
SpS0.07
BVpS1.28
TBVpS1.28
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -175.1%
ROE -406.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 789.74%
FCFM N/A
ROA(3y)-59.16%
ROA(5y)-45.97%
ROE(3y)-93.94%
ROE(5y)-84.6%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.76%
GM growth 5Y-2.54%
F-Score1
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.61%
Cap/Sales 60.89%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.93
Quick Ratio 1.93
Altman-Z -4.35
F-Score1
WACC6.81%
ROIC/WACCN/A
Cap/Depr(3y)175.27%
Cap/Depr(5y)145.6%
Cap/Sales(3y)18.76%
Cap/Sales(5y)12.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.25%
EPS Next Y40.97%
EPS Next 2Y28.77%
EPS Next 3Y19.02%
EPS Next 5Y11.18%
Revenue 1Y (TTM)-95.39%
Revenue growth 3Y-33.67%
Revenue growth 5Y-19%
Sales Q2Q%-92.1%
Revenue Next Year-81.84%
Revenue Next 2Y-23.09%
Revenue Next 3Y14.98%
Revenue Next 5Y35.57%
EBIT growth 1Y42.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-8.45%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y25.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24.28%
OCF growth 3YN/A
OCF growth 5YN/A

AFFIMED NV / AFMD Fundamental Analysis FAQ

What is the fundamental rating for AFMD stock?

ChartMill assigns a fundamental rating of 2 / 10 to AFMD.


What is the valuation status of AFFIMED NV (AFMD) stock?

ChartMill assigns a valuation rating of 0 / 10 to AFFIMED NV (AFMD). This can be considered as Overvalued.


Can you provide the profitability details for AFFIMED NV?

AFFIMED NV (AFMD) has a profitability rating of 1 / 10.